Northwest Bioth Cmn (NWBO)

$0.29 0.00 (-1.09%)
Market Cap 472.30M
Revenue (ttm) 1.38M
Net Income (ttm) -83.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,071.01%
Debt to Equity Ratio 0.00
Volume 2,578,300
Avg Vol 3,549,004
Day's Range N/A - N/A
Shares Out 1.58B
Stochastic %K 52%
Beta -0.86
Analysts Strong Buy
Price Target $2.00

Company Profile

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inop...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 497 9024
Address:
4800 Montgomery Lane, Suite 800, Bethesda, United States
TheDanishDude
TheDanishDude Jan. 28 at 12:19 AM
$NWBO A poster on Ihub today wrote “While we once dreamed big, the continuous dilution and the prolonged approval process have tempered those expectations. Some posters, however, don’t seem to factor in the current outstanding share count compared to a few years ago. If their views are hard to accept, it’s often easier to stick with posters you trust or remain neutral” I just don’t get that. 🤔 So I would like to counter that. NWBO is at an IMMENSELY better place today - valuation wise - compared to TLD 2022 and I’m not afraid of calling it “outrunning dilution”. Analysis: http://bit.ly/4a1B3NC
2 · Reply
chris57
chris57 Jan. 27 at 10:54 PM
$NWBO you don’t even know what “it” is… but thanks for sharing your analysis.
1 · Reply
Twister8
Twister8 Jan. 27 at 10:30 PM
$NWBO
0 · Reply
Finger_roll_
Finger_roll_ Jan. 27 at 10:01 PM
$NWBO https://x.com/rip_gop1234/status/2016240591433036124?s=46&t=UFIiLnhBJ2MHTM-sDhsXfw
0 · Reply
yensid
yensid Jan. 27 at 9:18 PM
$NWBO 🤔
0 · Reply
JGHersh
JGHersh Jan. 27 at 8:33 PM
$NWBO these Penny flippers just make me laugh. Wait until the stock explodes.
1 · Reply
chris57
chris57 Jan. 27 at 8:30 PM
$NWBO Why $10-20/share isn't unreasonable in an all-stock deal: At $15/share, that's ~$22B. Sounds huge for an OTC stock. But look at what an acquirer actually gets: First-to-market approved cancer vaccine. Roswell Park IP designed to enhance checkpoint inhibitors. Owned manufacturing ready to scale. Platform data across 20+ tumor types. Keytruda does $25B/year but only works in ~20% of solid tumors. If Kalinski's DC technology expands that to 35-40%, you've added tens of billions in franchise value. Merck paid $11B for Acceleron and $10.8B for Prometheus — narrower platforms than this. In a bidding war where Merck is defending Keytruda's future against Pfizer or BMS, $20-30B is strategic defense, not overpayment. And in an all-stock deal, the acquirer pays with paper, shareholders get tax-free rollover, and interests align. Everyone wins. DanishDude calling for $40 per share… he knows who's circling.
3 · Reply
chris57
chris57 Jan. 27 at 8:27 PM
$NWBO Why the Cancer Vaccine Coalition summit matters for NWBO: NWBO is one of four sponsors, alongside Pfizer, of a first-of-its-kind AACR-partnered think tank on therapeutic cancer vaccines. 50+ top researchers, pharma executives, and regulatory experts are in the room. The featured patient testimonial? Brad Silver—diagnosed with stage IV glioblastoma in 2003, given two months to live, treated with DCVax-L at UCLA. He's still here 22 years later. This isn't a poster session at a minor conference. This is NWBO being positioned at the center of a coordinated push to bring cancer vaccines to patients—with Pfizer money backing the effort and AACR lending institutional weight. The timing isn't accidental. MHRA approval is imminent. This is how you build the ecosystem for commercialization and signal to potential acquirers that DCVax is the real thing.
1 · Reply
sDinvestments1
sDinvestments1 Jan. 27 at 8:27 PM
$NWBO I asked what title sponsor meant. This is the answer. “Title sponsor” means the top-tier sponsor whose name is most prominently associated with the event—often treated as the event’s primary commercial backer. In practical terms, a title sponsor usually gets: • 🏷 Name association with the event (sometimes “Event Name presented by X”) • ⭐ Highest visibility in marketing, signage, and programs • 🎤 Prominent speaking or hosting roles • 🤝 Influence on themes, panels, or strategic direction (not scientific control, but agenda emphasis) • 💰 Largest financial contribution compared to other sponsors In the AACR post you shared: • Northwest Biotherapeutics = Title Sponsor • Pfizer = Gold Sponsor • Anixa = Biotech Sponsor • & Cure = Silver Sponsor That hierarchy signals both funding level and prominence, not scientific endorsement or regulatory favoritism.
7 · Reply
wjmax
wjmax Jan. 27 at 8:20 PM
$NWBO https://youtu.be/Ei8qgRIUE6I?feature=shared
0 · Reply
Latest News on NWBO
No data available.
TheDanishDude
TheDanishDude Jan. 28 at 12:19 AM
$NWBO A poster on Ihub today wrote “While we once dreamed big, the continuous dilution and the prolonged approval process have tempered those expectations. Some posters, however, don’t seem to factor in the current outstanding share count compared to a few years ago. If their views are hard to accept, it’s often easier to stick with posters you trust or remain neutral” I just don’t get that. 🤔 So I would like to counter that. NWBO is at an IMMENSELY better place today - valuation wise - compared to TLD 2022 and I’m not afraid of calling it “outrunning dilution”. Analysis: http://bit.ly/4a1B3NC
2 · Reply
chris57
chris57 Jan. 27 at 10:54 PM
$NWBO you don’t even know what “it” is… but thanks for sharing your analysis.
1 · Reply
Twister8
Twister8 Jan. 27 at 10:30 PM
$NWBO
0 · Reply
Finger_roll_
Finger_roll_ Jan. 27 at 10:01 PM
$NWBO https://x.com/rip_gop1234/status/2016240591433036124?s=46&t=UFIiLnhBJ2MHTM-sDhsXfw
0 · Reply
yensid
yensid Jan. 27 at 9:18 PM
$NWBO 🤔
0 · Reply
JGHersh
JGHersh Jan. 27 at 8:33 PM
$NWBO these Penny flippers just make me laugh. Wait until the stock explodes.
1 · Reply
chris57
chris57 Jan. 27 at 8:30 PM
$NWBO Why $10-20/share isn't unreasonable in an all-stock deal: At $15/share, that's ~$22B. Sounds huge for an OTC stock. But look at what an acquirer actually gets: First-to-market approved cancer vaccine. Roswell Park IP designed to enhance checkpoint inhibitors. Owned manufacturing ready to scale. Platform data across 20+ tumor types. Keytruda does $25B/year but only works in ~20% of solid tumors. If Kalinski's DC technology expands that to 35-40%, you've added tens of billions in franchise value. Merck paid $11B for Acceleron and $10.8B for Prometheus — narrower platforms than this. In a bidding war where Merck is defending Keytruda's future against Pfizer or BMS, $20-30B is strategic defense, not overpayment. And in an all-stock deal, the acquirer pays with paper, shareholders get tax-free rollover, and interests align. Everyone wins. DanishDude calling for $40 per share… he knows who's circling.
3 · Reply
chris57
chris57 Jan. 27 at 8:27 PM
$NWBO Why the Cancer Vaccine Coalition summit matters for NWBO: NWBO is one of four sponsors, alongside Pfizer, of a first-of-its-kind AACR-partnered think tank on therapeutic cancer vaccines. 50+ top researchers, pharma executives, and regulatory experts are in the room. The featured patient testimonial? Brad Silver—diagnosed with stage IV glioblastoma in 2003, given two months to live, treated with DCVax-L at UCLA. He's still here 22 years later. This isn't a poster session at a minor conference. This is NWBO being positioned at the center of a coordinated push to bring cancer vaccines to patients—with Pfizer money backing the effort and AACR lending institutional weight. The timing isn't accidental. MHRA approval is imminent. This is how you build the ecosystem for commercialization and signal to potential acquirers that DCVax is the real thing.
1 · Reply
sDinvestments1
sDinvestments1 Jan. 27 at 8:27 PM
$NWBO I asked what title sponsor meant. This is the answer. “Title sponsor” means the top-tier sponsor whose name is most prominently associated with the event—often treated as the event’s primary commercial backer. In practical terms, a title sponsor usually gets: • 🏷 Name association with the event (sometimes “Event Name presented by X”) • ⭐ Highest visibility in marketing, signage, and programs • 🎤 Prominent speaking or hosting roles • 🤝 Influence on themes, panels, or strategic direction (not scientific control, but agenda emphasis) • 💰 Largest financial contribution compared to other sponsors In the AACR post you shared: • Northwest Biotherapeutics = Title Sponsor • Pfizer = Gold Sponsor • Anixa = Biotech Sponsor • & Cure = Silver Sponsor That hierarchy signals both funding level and prominence, not scientific endorsement or regulatory favoritism.
7 · Reply
wjmax
wjmax Jan. 27 at 8:20 PM
$NWBO https://youtu.be/Ei8qgRIUE6I?feature=shared
0 · Reply
JGHersh
JGHersh Jan. 27 at 8:11 PM
$NWBO I meant to say day by day, little by little I keep adding to the shares that i own
1 · Reply
JGHersh
JGHersh Jan. 27 at 8:09 PM
$NWBO little by little day by day I just keep Addie to the shares.
1 · Reply
TheWayISeeIt
TheWayISeeIt Jan. 27 at 8:05 PM
$NWBO “One such example is Brad Silver, who received a therapeutic cancer vaccine for stage IV glioblastoma in 2003. At the time, he was given just two months to live. Twenty-two years later, Silver is thriving. "I am not supposed to be here," said Silver, who was treated in an early stage clinical trial of DCVax-L at UCLA.”
0 · Reply
Makeitcometrue
Makeitcometrue Jan. 27 at 8:04 PM
$NWBO 😂😂😂😂😂😂just read TLD from 5/10/22 and that warm feeling subsides monoploy share holder😂😂😂😂😂
0 · Reply
TheWayISeeIt
TheWayISeeIt Jan. 27 at 8:03 PM
$NWBO https://www.prnewswire.com/news-releases/top-cancer-researchers-join-forces-to-advance-development-of-therapeutic-cancer-vaccines-302671365.html
0 · Reply
knowsray
knowsray Jan. 27 at 8:01 PM
$NWBO https://www.prnewswire.com/news-releases/top-cancer-researchers-join-forces-to-advance-development-of-therapeutic-cancer-vaccines-302671365.html
0 · Reply
Cpizza
Cpizza Jan. 27 at 7:57 PM
$NWBO we learn from everybody, even fudsers there was a company called Ampio pharmaceuticals I wish I listen to the fudsters I'd be in a lot better place today. We know a lot, but we don't know everything and we may not agree with everybody, but we shouldn't discount them.
4 · Reply
Jjscans
Jjscans Jan. 27 at 7:43 PM
$NWBO
0 · Reply
Driley910
Driley910 Jan. 27 at 7:37 PM
$NWBO
0 · Reply
Paffus
Paffus Jan. 27 at 7:08 PM
$NWBO HSBC Innovation Banking has many skills. So they can help Nwbo and us all the way.👇
0 · Reply
tinman0319
tinman0319 Jan. 27 at 7:06 PM
$NWBO https://cancervaccinecoalition.org/ Just read the top line from the Editor In Chief of Jama Oncology it makes me feel so warm inside
2 · Reply
chris57
chris57 Jan. 27 at 6:53 PM
$NWBO bought 100k more shares. Sold some PSLV for a nice 100% gain. Holding onto my physical stack and NWBO shares till death. My bet: buyout in all stock deal. My plan: buy, borrow, die. Those big pharma dividends sure look nice.
0 · Reply